Abstract:Migraine, a prevalent neurological disorder, affects approximately 14.1% of the global population and disproportionately impacts females. This debilitating condition significantly compromises quality of life, productivity, and incurs high healthcare costs, presenting a challenge not only to individuals but to societal structures as a whole. Despite advances in our understanding of migraine pathophysiology, treatment options remain limited, necessitating ongoing research into effective therapies. This review delves into the complexity of migraine management, examining the roles of genetic predisposition, environmental influences, personalized treatment approaches, comorbidities, efficacy and safety of existing acute and preventive treatments. It further explores the continuum between migraine and tension-type headaches and discusses the intricacies of treating various migraine subtypes, including those with and without aura. We emphasize the recent paradigm shift toward trigeminovascular activation and the release of vasoactive substances, such as calcitonin gene-related peptide (CGRP), which offer novel therapeutic targets. We assess groundbreaking clinical trials, pharmacokinetic and pharmacodynamic perspectives, safety, tolerability, and the real-world application of CGRP monoclonal antibodies and gepants. In the face of persisting treatment barriers such as misdiagnosis, medication overuse headaches, and limited access to specialist care, we discuss innovative CGRP-targeted strategies, the high cost and scarcity of long-term efficacy data, and suggest comprehensive solutions tailored to Turkiye and developing countries. The review offers strategic recommendations including the formulation of primary care guidelines, establishment of specialized outpatient clinics, updating physicians on novel treatments, enhancing global accessibility to advanced therapies, and fostering patient education. Emphasizing the importance of lifestyle modifications and holistic approaches, the review underscores the potential of mass media and patient groups in disseminating critical health information and shaping the future of migraine management.

Migraine: Advances in the Pathogenesis and Treatment

Migraine Treatment: Towards New Pharmacological Targets

Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives

Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implications

Novel Therapeutic Targets for Migraine

Migraine: Pathophysiology, Pharmacology, Treatment and Future Trends

The pathophysiology of migraine: implications for clinical management

Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors

Molecular nociceptive mechanisms in migraine: The migraine cascade

Potential treatment targets for migraine: emerging options and future prospects

Future targets for migraine treatment beyond CGRP

Migraine: Multiple Processes, Complex Pathophysiology

Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second‐Generation Gepants, and Cardiovascular Risk

New perspectives on migraine treatment: a review of the mechanisms and effects of complementary and alternative therapies

Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics

Migraine Treatment: When, Why, and How to Introduce Antimigraine Therapies

Advances in Pharmaceutic Managements of Migraine

Hallmarks of primary headache: part 1 – migraine

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond

The prodrome of migraine: mechanistic insights and emerging therapeutic strategies

An update on migraine